South San Francisco, CA – According to filings with the U.S. Securities and Exchange Commission, Interline Therapeutics is raising $50,000,000.00 in new funding. Sources indicate as part of senior management President and Chief Executive Officer, Zachary Sweeney played a key role in securing the recent investment and it will aid in aggressively expanding the company, as well as broaden and accelerate product development.

About Interline Therapeutics
Interline Therapeutics is a drug discovery company focused on systematically elucidating protein communities to define molecular mechanisms of disease. Based on these insights, we are discovering new medicines to treat cancer and inflammatory diseases. Interline is headquartered in South San Francisco, CA. Proteins are typically studied as isolated entities, but in nature function in protein communities interconnected networks of dynamic protein interactions. Medical research has been limited by an incomplete understanding of how these networks impact diseases. Interline is developing a precision medicine platform to map and modulate protein communities, leveraging recent advancements in genomics, proteomics, structural biology and computational chemistry.

To learn more about Interline Therapeutics, visit http://www.interlinetx.com/

Contact:
Zachary Sweeney, President and Chief Executive Officer
415-787-6009
zsweeney@interlinetx.com
https://www.linkedin.com/in/zachary-sweeney-5b7ab61a/

SOURCE: http://www.intelligence360.io
Copyright (c) 2021 SI360 Inc. All rights reserved